MSLHP
MCID: MSC007
MIFTS: 58

Muscle Hypertrophy (MSLHP) malady

Categories: Genetic diseases, Rare diseases, Muscle diseases

Aliases & Classifications for Muscle Hypertrophy

Aliases & Descriptions for Muscle Hypertrophy:

Name: Muscle Hypertrophy 54 66 13
Hypertrophy 42 69
Myostatin-Related Muscle Hypertrophy 56
Muscle Hypertrophy Syndrome 29
Mslhp 66

Characteristics:

Orphanet epidemiological data:

56
myostatin-related muscle hypertrophy
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

HPO:

32
muscle hypertrophy:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 54 614160
Orphanet 56 ORPHA275534
UMLS via Orphanet 70 C2931112
MedGen 40 CN069079

Summaries for Muscle Hypertrophy

UniProtKB/Swiss-Prot : 66 Muscle hypertrophy: A condition characterized by increased muscle bulk and strength. Affected individuals are exceptionally strong.

MalaCards based summary : Muscle Hypertrophy, also known as hypertrophy, is related to myostatin-related muscle hypertrophy and adenoid hypertrophy, and has symptoms including skeletal muscle hypertrophy, cachexia and cyanosis. An important gene associated with Muscle Hypertrophy is MSTN (Myostatin), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Eplerenone and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, smooth muscle and heart, and related phenotypes are Decreased viability with paclitaxel and cardiovascular system

Wikipedia : 71 Muscle hypertrophy involves an increase in size of skeletal muscle through a growth in size of its... more...

Description from OMIM: 614160

Related Diseases for Muscle Hypertrophy

Diseases in the Muscle Hypertrophy family:

Myostatin-Related Muscle Hypertrophy

Diseases related to Muscle Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Related Disease Score Top Affiliating Genes
1 myostatin-related muscle hypertrophy 12.4
2 adenoid hypertrophy 12.2
3 myopathy, x-linked, with postural muscle atrophy 10.8
4 muscular dystrophy, congenital, 1b 10.7
5 myhre syndrome 10.7
6 muscular dystrophy-dystroglycanopathy , type b, 5 10.7
7 narrow oral fissure short stature cone shaped epiphyses 10.1 MYH6 MYH7
8 limb ischemia 10.1 EDN1 IGF1 LEP
9 diabetic encephalopathy 10.1 EDN1 IGF1 LEP
10 micturation-induced seizures 10.0 AGT MYH6
11 childhood ataxia with central nervous system hypomyelination/vanishing white matter 10.0 MYH6 MYH7
12 eastern equine encephalitis 10.0 AGT EDN1 NPPA
13 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.0 AGT MYH7 NPPA
14 welander distal myopathy 10.0 AGT EDN1 LEP
15 critical limb ischemia 9.9 EDN1 MYH6 MYH7 NPPA
16 neu-laxova syndrome 2 9.8 FHL1 MYOD1
17 myotonia congenita 9.8
18 muscular dystrophy 9.8
19 cardiomyopathy 9.8
20 myotonia 9.8
21 xanthogranulomatous pyelonephritis 9.8 EDN1 MEF2A MYH6 MYH7 NPPA
22 neuropathy 9.7
23 becker muscular dystrophy 9.7
24 hypertension, essential 9.7 AGT EDN1 LEP NPPA SLC9A1
25 radiculopathy 9.7
26 multifocal motor neuropathy 9.7
27 cerebral angioma 9.6 FBXO32 MSTN MYOD1
28 spinal muscular atrophy 9.5
29 cardiac arrest 9.5
30 oral submucous fibrosis 9.5
31 myositis 9.5
32 cysticercosis 9.5
33 muscular atrophy 9.5
34 mononeuropathy 9.5
35 esophagitis 9.5
36 multiple myeloma 9.5
37 entropion 9.5
38 dysferlinopathy 9.5
39 tarsal tunnel syndrome 9.5
40 glucagonoma 9.5
41 hypertrophic pyloric stenosis 9.5
42 primary orthostatic tremor 9.5
43 pyloric stenosis 9.5
44 duchenne muscular dystrophy 9.5
45 hiatus hernia 9.5
46 myoclonus 9.5
47 vertebrobasilar insufficiency 9.5
48 pulmonary hypertension 9.5
49 urethritis 9.5
50 tremor 9.5

Graphical network of the top 20 diseases related to Muscle Hypertrophy:



Diseases related to Muscle Hypertrophy

Symptoms & Phenotypes for Muscle Hypertrophy

Clinical features from OMIM:

614160

Human phenotypes related to Muscle Hypertrophy:

32
id Description HPO Frequency HPO Source Accession
1 skeletal muscle hypertrophy 32 HP:0003712

UMLS symptoms related to Muscle Hypertrophy:


cachexia, cyanosis, dyspnea, edema, fever, headache, hepatosplenomegaly, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, hot flushes

GenomeRNAi Phenotypes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 IGF1 MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR

MGI Mouse Phenotypes related to Muscle Hypertrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 IGF1 LEP MEF2A MSTN MTOR MYH6
2 growth/size/body region MP:0005378 10.22 AGT EDN1 FHL1 GATA6 GSK3B HDAC4
3 homeostasis/metabolism MP:0005376 10.18 IGF1 LEP MSTN MTOR MYH6 MYOD1
4 behavior/neurological MP:0005386 10.16 AGT FHL1 GSK3B HDAC4 LEP MEF2A
5 mortality/aging MP:0010768 10.13 SLC9A1 AGT EDN1 GATA6 GSK3B HDAC4
6 muscle MP:0005369 10.13 AGT EDN1 FBXO32 FHL1 GATA6 HDAC4
7 adipose tissue MP:0005375 9.95 AGT IGF1 LEP MSTN MTOR MYOD1
8 nervous system MP:0003631 9.85 HDAC4 IGF1 LEP MEF2A MTOR SLC9A1
9 normal MP:0002873 9.56 EDN1 GATA6 GSK3B IGF1 MEF2A MTOR
10 renal/urinary system MP:0005367 9.23 MSTN MTOR NPPA AGT EDN1 GSK3B

Drugs & Therapeutics for Muscle Hypertrophy

Drugs for Muscle Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 590)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eplerenone Approved Phase 4 107724-20-9 150310 443872
2
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
5
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
6
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
7
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
8
Timolol Approved Phase 4 26839-75-8 33624 5478
9
Travoprost Approved Phase 4 157283-68-6 5282226
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
11
Ticlopidine Approved Phase 4 55142-85-3 5472
12
Citalopram Approved Phase 4 59729-33-8 2771
13
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
14
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
15
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
16
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2 81403-80-7 2092
17
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
18
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 1 106133-20-4 129211
19
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
20
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
23
Indapamide Approved Phase 4 26807-65-8 3702
24
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
25
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
26
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
27
Ephedrine Approved Phase 4 299-42-3 9294
28
Oxymetazoline Approved Phase 4,Phase 3,Phase 2 1491-59-4 4636
29
Phenylephrine Approved Phase 4,Phase 3,Phase 2 59-42-7 6041
30
Pseudoephedrine Approved Phase 4 90-82-4 7028
31
Allopurinol Approved Phase 4 315-30-0 2094
32
Petrolatum Approved Phase 4 8009-03-8
33
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3 138402-11-6 3749
34
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2 164656-23-9 152945 6918296
35
Felodipine Approved, Investigational Phase 4,Phase 3 72509-76-3 3333
36
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
37
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-23-7 5754 657311
38
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
39
Captopril Approved Phase 4 62571-86-2 44093
40
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
41
Silodosin Approved Phase 4 160970-54-7
42
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
43
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
44
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
45
Budesonide Approved Phase 4 51333-22-3 63006 5281004
46
Montelukast Approved Phase 4,Phase 3 158966-92-8 5281040
47
Clonidine Approved Phase 4 4205-90-7 2803
48
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
49
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
50
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078

Interventional clinical trials:

(show top 50) (show all 922)
id Name Status NCT ID Phase
1 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4
2 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4
3 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Unknown status NCT00879060 Phase 4
4 An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix) Unknown status NCT01004536 Phase 4
5 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4
6 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4
7 Randomized Controlled Study of Plasmaknife Tonsillectomy Versus Monopolar Tonsillectomy Unknown status NCT00466544 Phase 4
8 Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery Unknown status NCT01046604 Phase 4
9 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4
10 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4
11 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4
12 Home Blood Pressure in Hypertension Management Unknown status NCT00841308 Phase 4
13 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4
14 THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure Unknown status NCT01640639 Phase 4
15 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Unknown status NCT01927406 Phase 4
16 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure Unknown status NCT01156207 Phase 4
17 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4
18 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4
19 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4
20 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
21 Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension Completed NCT00139555 Phase 4
22 Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy Completed NCT02559440 Phase 4
23 Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT01425411 Phase 4
24 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4
25 Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery Completed NCT02487212 Phase 4
26 I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT00362037 Phase 4
27 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4
28 Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367) Completed NCT01098071 Phase 4
29 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4
30 Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars Completed NCT01078428 Phase 4
31 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4
32 Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) Completed NCT00348686 Phase 4
33 A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Completed NCT00754247 Phase 4
34 Ranolazine for the Treatment of Chest Pain in HCM Patients Completed NCT01721967 Phase 4
35 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4
36 Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients Completed NCT00974857 Phase 4
37 ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling Completed NCT01176032 Phase 4
38 Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Completed NCT01144039 Phase 4
39 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
40 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4
41 Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease Completed NCT00548912 Phase 4
42 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4
43 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4
44 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4
45 EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure Completed NCT00338000 Phase 4
46 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children Completed NCT00912171 Phase 4
47 Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery Completed NCT01946087 Phase 4
48 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4
49 Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study Completed NCT00421863 Phase 4
50 VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients Completed NCT00169910 Phase 4

Search NIH Clinical Center for Muscle Hypertrophy

Cochrane evidence based reviews: hypertrophy

Genetic Tests for Muscle Hypertrophy

Genetic tests related to Muscle Hypertrophy:

id Genetic test Affiliating Genes
1 Muscle Hypertrophy 29

Anatomical Context for Muscle Hypertrophy

MalaCards organs/tissues related to Muscle Hypertrophy:

39
Skeletal Muscle, Smooth Muscle, Heart

Publications for Muscle Hypertrophy

Articles related to Muscle Hypertrophy:

(show top 50) (show all 141)
id Title Authors Year
1
Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts during Skeletal Muscle Hypertrophy. ( 27840022 )
2017
2
Satellite Cells Contribution to Exercise Mediated Muscle Hypertrophy and Repair. ( 28042532 )
2017
3
Post-exercise blood flow restriction attenuates muscle hypertrophy. ( 27480315 )
2016
4
Neurogenic muscle hypertrophy: a case report. ( 27738507 )
2016
5
Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. ( 27225984 )
2016
6
Impact of high versus low fixed loads and non-linear training loads on muscle hypertrophy, strength and force development. ( 27350928 )
2016
7
Conditional Loss of Pten in Myogenic Progenitors Leads to Postnatal Skeletal Muscle Hypertrophy but Age-Dependent Exhaustion of Satellite Cells. ( 27880908 )
2016
8
Intramuscular Anabolic Signaling and Endocrine Response Following Resistance Exercise: Implications for Muscle Hypertrophy. ( 26666743 )
2016
9
Multiplex gene editing via CRISPR/Cas9 exhibits desirable muscle hypertrophy without detectable off-target effects in sheep. ( 27562433 )
2016
10
Integrated expression analysis of muscle hypertrophy identifies Asb2 as a negative regulator of muscle mass. ( 27182554 )
2016
11
Ribosome Biogenesis is Necessary for Skeletal Muscle Hypertrophy. ( 27135313 )
2016
12
Exome Sequencing Identified a Splice Site Mutation in FHL1 that Causes Uruguay Syndrome, an X-Linked Disorder With Skeletal Muscle Hypertrophy and Premature Cardiac Death. ( 26933038 )
2016
13
The effects of resistance exercise on cocaine self-administration, muscle hypertrophy, and BDNF expression in the nucleus accumbens. ( 27137405 )
2016
14
CL316,243, a I^3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength. ( 27874066 )
2016
15
Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle. ( 27246614 )
2016
16
Modeling Energy Dynamics in Mice with Skeletal Muscle Hypertrophy Fed High Calorie Diets. ( 27076790 )
2016
17
AMPKI^3 is dispensable for skeletal muscle hypertrophy induced by functional overload. ( 26758685 )
2016
18
Changes in muscle fiber contractility and extracellular matrix production during skeletal muscle hypertrophy. ( 27979985 )
2016
19
Mechanisms of resistance exercise-induced muscle hypertrophy: 'You can't make an omelette without breaking eggs'. ( 27976401 )
2016
20
Effects of morning versus evening combined strength and endurance training on physical performance, muscle hypertrophy, and serum hormone concentrations. ( 27863207 )
2016
21
Exercise quantity-dependent muscle hypertrophy in adult zebrafish (Danio rerio). ( 26951149 )
2016
22
The problem Of muscle hypertrophy: Revisited. ( 27717161 )
2016
23
Recurrent parotid swelling secondary to masseter muscle hypertrophy: a multidisciplinary diagnostic and therapeutic approach. ( 26892838 )
2016
24
An intricate balance of muscle damage and protein synthesis: the key players in skeletal muscle hypertrophy following resistance training. ( 27976396 )
2016
25
Letter to the Editor: Can muscle hypertrophy cause entrapment neuropathy? ( 27419828 )
2016
26
Frequency: The Overlooked Resistance Training Variable for Inducing Muscle Hypertrophy? ( 27752983 )
2016
27
Transcriptional profiling of rat skeletal muscle hypertrophy under restriction of blood flow. ( 27613141 )
2016
28
Housekeeping proteins: How useful are they in skeletal muscle diabetes studies and muscle hypertrophy models? ( 27060530 )
2016
29
Effect of previous strength training episode and retraining on facilitation of skeletal muscle hypertrophy and contractile properties after long-term detraining in rats. ( 27162768 )
2016
30
Effects of rest intervals and training loads on metabolic stress and muscle hypertrophy. ( 28032435 )
2016
31
Passive Muscle Movements Combined With Blood Flow Restriction Can Induce Muscle Hypertrophy: 1709 Board #362 June 2, 9: 00 AM - 10: 30 AM. ( 27360628 )
2016
32
Comparative Analyses between Skeletal Muscle miRNAomes from Large White and Min Pigs Revealed MicroRNAs Associated with Postnatal Muscle Hypertrophy. ( 27253583 )
2016
33
Training to Fatigue: The Answer for Standardization When Assessing Muscle Hypertrophy? ( 27677915 )
2016
34
Effects of Resistance Training Frequency on Measures of Muscle Hypertrophy: A Systematic Review and Meta-Analysis. ( 27102172 )
2016
35
Muscle hypertrophy as the presenting sign in a patient with a complete FHL1 deletion. ( 27409453 )
2016
36
PRENATAL MYONUCLEI PLAY A CRUCIAL ROLE FOR SKELETAL MUSCLE HYPERTROPHY IN RODENTS. ( 27927611 )
2016
37
The dose-response relationship between resistance training volume and muscle hypertrophy: are there really still any doubts? ( 27805470 )
2016
38
Neurogenic muscle hypertrophy in a 12-year-old girl. ( 27449889 )
2016
39
Responses of skeletal muscle hypertrophy in Wistar rats to different resistance exercise models. ( 27982685 )
2016
40
Skeletal Muscle Hypertrophy with Concurrent Exercise Training: Contrary Evidence for an Interference Effect. ( 26932769 )
2016
41
Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: Case-control Study with a Pair of Identical Twins. ( 27088469 )
2016
42
Reduced Notch signalling leads to postnatal skeletal muscle hypertrophy in Pofut1cax/cax mice. ( 27628322 )
2016
43
Blood flow-restricted walking in older women: does the acute hormonal response associate with muscle hypertrophy? ( 26517965 )
2015
44
Identification of a Novel Four and a Half LIM Domain 1 Mutation in a Chinese Male Presented with Hypertrophic Cardiomyopathy and Mild Skeletal Muscle Hypertrophy. ( 26265627 )
2015
45
Biomechanical implications of skeletal muscle hypertrophy and atrophy: a musculoskeletal model. ( 26644989 )
2015
46
Contribution of muscle hypertrophy to strength gain after training in elderly adults. ( 26252190 )
2015
47
Accessory papillary muscles and papillary muscle hypertrophy are associated with sudden cardiac arrest of unknown cause. ( 26142977 )
2015
48
Vitamin supplementation and resistance exercise-induced muscle hypertrophy: shifting the redox balance scale? ( 26173824 )
2015
49
The findings of Damas et al. have not influenced the previously proposed time course of skeletal muscle hypertrophy. ( 26497192 )
2015
50
Painless acrocyanosis: Paget-Schroetter syndrome secondary to thoracic outlet obstruction from muscle hypertrophy, a case report. ( 26763826 )
2015

Variations for Muscle Hypertrophy

ClinVar genetic disease variations for Muscle Hypertrophy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MSTN NM_005259.2(MSTN): c.373+5G> A single nucleotide variant Pathogenic rs397515373 GRCh37 Chromosome 2, 190926945: 190926945

Expression for Muscle Hypertrophy

Search GEO for disease gene expression data for Muscle Hypertrophy.

Pathways for Muscle Hypertrophy

Pathways related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 AGT EDN1 GSK3B IGF1 MEF2A MTOR
2
Show member pathways
12.18 GSK3B HDAC4 IGF1 LEP MTOR
3 11.9 HDAC4 MEF2A MTOR SLC9A1
4 11.85 AGT IGF1 LEP MEF2A
5 11.77 GSK3B MTOR MYH6 SLC9A1
6 11.74 GSK3B IGF1 MTOR
7
Show member pathways
11.7 HDAC4 IGF1 MEF2A MTOR MYOD1
8 11.68 IGF1 LEP MYOD1
9 11.58 MYH6 MYH7 SLC9A1
10 11.55 EDN1 IGF1 MTOR NPPA
11
Show member pathways
11.43 AGT EDN1 GSK3B HDAC4 IGF1 MEF2A
12 11.4 GSK3B IGF1 MYH6
13
Show member pathways
10.91 EDN1 IGF1 MTOR
14 10.85 FBXO32 GSK3B IGF1 MSTN MTOR

GO Terms for Muscle Hypertrophy

Cellular components related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 AGT EDN1 FBXO32 FHL1 GSK3B HDAC4
2 sarcomere GO:0030017 9.43 HDAC4 MYH6 MYH7
3 myofibril GO:0030016 9.33 MYH6 MYH7 MYOD1
4 Z disc GO:0030018 8.92 FBXO32 HDAC4 MYH6 MYH7

Biological processes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 41)
id Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.85 AGT LEP NPPA
2 cellular response to hypoxia GO:0071456 9.85 EDN1 GATA6 MTOR SLC9A1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 AGT IGF1 MTOR
4 positive regulation of protein kinase B signaling GO:0051897 9.83 LEP MTOR MYOC
5 response to insulin GO:0032868 9.8 LEP MTOR NPPA
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 AGT IGF1 LEP MYOC
7 cardiac muscle contraction GO:0060048 9.75 MTOR MYH6 MYH7
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.74 AGT EDN1 MTOR
9 regulation of heart rate GO:0002027 9.73 AGT MYH6 MYH7
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 EDN1 HDAC4 IGF1 MTOR
11 muscle organ development GO:0007517 9.72 FHL1 IGF1 MEF2A MSTN MYOD1
12 cell growth GO:0016049 9.71 EDN1 MTOR MTPN SLC9A1
13 regulation of blood vessel size GO:0050880 9.69 AGT EDN1 NPPA
14 regulation of stress fiber assembly GO:0051492 9.68 MYOC SLC9A1
15 energy reserve metabolic process GO:0006112 9.68 LEP MTOR
16 myotube differentiation GO:0014902 9.68 GSK3B MYOD1
17 positive regulation of renal sodium excretion GO:0035815 9.67 AGT EDN1
18 striated muscle cell differentiation GO:0051146 9.67 MTPN MYOD1
19 cellular sodium ion homeostasis GO:0006883 9.67 AGT SLC9A1
20 response to muscle stretch GO:0035994 9.67 EDN1 NPPA SLC9A1
21 adult heart development GO:0007512 9.66 MYH6 MYH7
22 cellular response to mechanical stimulus GO:0071260 9.65 AGT HDAC4 MTPN NPPA SLC9A1
23 response to denervation involved in regulation of muscle adaptation GO:0014894 9.64 FBXO32 HDAC4
24 artery smooth muscle contraction GO:0014824 9.64 AGT EDN1
25 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.63 IGF1 SLC9A1
26 cell growth involved in cardiac muscle cell development GO:0061049 9.62 AGT NPPA
27 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.62 HDAC4 SLC9A1
28 regulation of brown fat cell differentiation GO:0090335 9.61 LEP MTOR
29 negative regulation of NFAT protein import into nucleus GO:0051534 9.61 GSK3B MTOR
30 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.6 EDN1 IGF1
31 myotube cell development GO:0014904 9.59 IGF1 MYOD1
32 bone mineralization involved in bone maturation GO:0035630 9.58 IGF1 LEP
33 regulation of blood pressure GO:0008217 9.55 AGT EDN1 LEP MYH6 NPPA
34 negative regulation of myoblast proliferation GO:2000818 9.54 MSTN MYOD1
35 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.54 EDN1 IGF1 MTOR
36 cardiac muscle hypertrophy in response to stress GO:0014898 9.35 GATA6 HDAC4 MYH6 MYH7 NPPA
37 positive regulation of cardiac muscle hypertrophy GO:0010613 9.1 AGT EDN1 IGF1 MEF2A MTPN SLC9A1
38 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.13 EDN1 GATA6 GSK3B HDAC4 IGF1 MEF2A
39 negative regulation of apoptotic process GO:0043066 10.05 GATA6 GSK3B IGF1 LEP SLC9A1
40 positive regulation of cell proliferation GO:0008284 10.04 AGT EDN1 HDAC4 IGF1 LEP
41 positive regulation of transcription, DNA-templated GO:0045893 10.02 AGT GATA6 HDAC4 IGF1 MEF2A MSTN

Molecular functions related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.85 GATA6 HDAC4 MEF2A MTPN MYOD1
2 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.5 GATA6 MEF2A MYOD1
3 growth factor activity GO:0008083 9.46 AGT IGF1 LEP MSTN
4 RNA polymerase II transcription factor binding GO:0001085 9.43 GATA6 GSK3B MEF2A
5 protein kinase binding GO:0019901 9.43 GATA6 GSK3B HDAC4 MEF2A MTOR MYH6
6 actin-dependent ATPase activity GO:0030898 9.4 MYH6 MYH7
7 peptide hormone receptor binding GO:0051428 9.37 LEP NPPA
8 hormone activity GO:0005179 9.02 AGT EDN1 IGF1 LEP NPPA
9 protein binding GO:0005515 10.34 AGT EDN1 FBXO32 FHL1 GATA6 GSK3B

Sources for Muscle Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....